Acute Coronary Syndromes
Conference Coverage
AHA 2021 puts scientific dialogue, health equity center stage
The Scientific Sessions are fully online but with a heavy emphasis on live events and opportunities to interact globally over the latest...
Conference Coverage
At 5 years, iFR found as effective and safe as FFR for guiding PCI intervention
Five-year data reinforce prior finding: iFR and FFR are comparably effective and safe for guiding revascularization.
Conference Coverage
Short DAPT course beneficial after PCI in ‘bi-risk’ patients
MASTER DAPT subgroup analysis supports short antiplatelet course in cases of high bleeding and ischemic risk.
Conference Coverage
FAVOR III China: QFR-guided PCI shows advantage over angiography
Results from sham-controlled study strengthen support for using physiology to guide percutaneous coronary interventions, but external validation...
From the Journals
How applicable is ISCHEMIA trial to U.S. clinical practice?
A new study suggests that less than a third of U.S. patients with stable ischemic heart disease who currently undergo intervention would meet the...
Conference Coverage
FFR-guided PCI falls short vs. surgery in multivessel disease: FAME 3
PCI guided by FFR assessment may have yielded better outcomes in patients with less complex coronary anatomy, researchers say; others doubt the...
Conference Coverage
SUGAR trial finds superior stent for those with diabetes and CAD
In noninferiority trial, the Cre8 EVO stent was associated with fewer target lesion failures than the Resolute Onyx at 1 year in the setting of...
Guidelines
AHA/ACC issues first comprehensive guidance on chest pain
The clinical practice guideline offers a contemporary approach to determine which patients need further testing and which do not.
Conference Coverage
Real-world data favor invasive strategy for NSTEMI with CKD
The clinical benefits of initial invasive management came with a “minimal increased risk” of in-hospital acute kidney injury and major bleeding in...
From the Journals
Fluoroquinolones linked to sudden death risk for those on hemodialysis
Most patients undergoing hemodialysis have a least one risk factor for drug-induced QT interval prolongation.
From the Journals
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...